Table 2.
IBD patient characteristics
| n [%] | ||
|---|---|---|
| Type of IBD | Not specified | 3 [0.7%] |
| Crohn’s disease | 215 [51.8%] | |
| Ulcerative colitis | 192 [46.3%] | |
| IBDU | 5 [1.2%] | |
| Clinical activity of IBD | Remission | 233 [56.1%] |
| Mildly active | 127 [30.6%] | |
| Chronically active | 50 [12.0%] | |
| Flare | 2 [0.5%] | |
| IBD medication | ||
| Corticosteroids | 54 [13.0%] | |
| Mesalazine/sulfasalazine | 143 [34.5%] | |
| Anti-TNF | 99 [23.9%] | |
| Ustekinumab | 46 [11.1%] | |
| Vedolizumab | 49 [11.8%] | |
| JAK inhibitors | 14 [3.4%] | |
| Immunomodulators [azathioprine, 6-MP, MTX] | 70 [16.9%] | |
| Calcineurin inhibitors | 4 [1.0%] | |
| Other immunosuppression | 4 [1.0%] | |
| Total number of immunosuppressants | 0 | 149 [35.9%] |
| 1 | 212 [51.1%] | |
| 2 | 48 [11.6%] | |
| 3 | 6 [1.4%] |
IBDU, IBD unclassified; JAK, Janus kinase; MTX, methotrexate; Anti-TNF, anti-tumour necrosis factor alpha therapy; Other immunosuppression: guselkumab, eculizumab, chemotherapy for colon cancer, leflunomide.